Triferic is owned by Rockwell Medical Inc.
Triferic contains Ferric Pyrophosphate Citrate.
Triferic has a total of 2 drug patents out of which 0 drug patents have expired.
Triferic was authorised for market use on 25 April, 2016.
Triferic is available in for solution;intravenous dosage forms.
Triferic can be used as method of iron administration to treat patients in need of iron replacement.
The generics of Triferic are possible to be released after 17 April, 2029.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US7857977||ROCKWELL MEDICAL INC||Packaging of ferric pyrophosphate for dialysis|| |
(4 years from now)
|US7816404||ROCKWELL MEDICAL INC||Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions|| |
(5 years from now)
Drugs and Companies using FERRIC PYROPHOSPHATE CITRATE ingredient
Market Authorisation Date: 25 April, 2016
Treatment: Method of iron administration to treat patients in need of iron replacement
Dosage: FOR SOLUTION;INTRAVENOUS
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic